Transplantation and Cellular Therapy
Overview
Transplantation and Cellular Therapy is a peer-reviewed journal that focuses on the latest advancements in the field of transplantation and cellular therapy. It covers a wide range of topics including organ transplantation, stem cell transplantation, immunotherapy, regenerative medicine, and gene therapy. The journal provides a platform for researchers, clinicians, and scientists to share their findings, discuss innovative approaches, and explore new treatment options in this rapidly evolving field.
Details
Details
Abbr.
Transplant Cell Ther
Start
2021
End
Continuing
p-ISSN
2666-6375
e-ISSN
2666-6367
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 1640
140
SJR / Ranks: 1747
1602
CiteScore / Ranks: 2064
8.40
Recent Articles
1.
Smithy J, Schoenfeld A, Betof Warner A
Transplant Cell Ther
. 2025 Mar;
31(3S):S626-S634.
PMID: 40089331
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating...
2.
Lievense J, Nijenhuis C, Jedema I, Jonker-Hoogerkamp A, Moyers J, Hamid O, et al.
Transplant Cell Ther
. 2025 Mar;
31(3S):S610-S625.
PMID: 40089330
Tumor-infiltrating lymphocyte (TIL) medicinal products (MPs) show promise for treating solid tumors, especially metastatic melanoma, in the clinical trial setting. Through these studies, TIL developers have gained an immunological perspective...
3.
Tseng D, Lee S
Transplant Cell Ther
. 2025 Mar;
31(3S):S599-S609.
PMID: 40089329
In recent years, the successful use of tumor-infiltrating lymphocyte (TIL) therapy to treat melanoma not only culminated in a landmark Food and Drug Administration approval, but has also fueled the...
4.
Kirane A, Lee D, Ariyan C
Transplant Cell Ther
. 2025 Mar;
31(3S):S591-S598.
PMID: 40089328
Adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is a promising personalized immunotherapy approach, spearheaded by Dr. Steven Rosenberg, targeting various cancer types. Despite initial challenges in TIL production,...
5.
Shoushtari A, Powell D
Transplant Cell Ther
. 2025 Mar;
31(3S):S581-S590.
PMID: 40089327
Lifileucel, the first solid tumor adoptive tumor infiltrating lymphocyte (TIL) therapy product to receive regulatory approval in advanced melanoma, represents a critical achievement in the pursuit of improving outcomes using...
6.
Chorao P, Pardal A, de Cossio S, Balaguer-Rosello A, Montoro J, Villalba M, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40068801
Background: Despite the high incidence of diarrhea in hematopoietic cell transplant (HCT) recipients, data on infectious enterocolitis with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis remain limited. Objectives: Evaluate...
7.
Schroeder T, Flossdorf S, Schuh C, Pabst C, Stadler M, Schetelig J, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40058648
Mutations in isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are found in 15% to 20% of patients with acute myeloid leukemia (AML). IDH inhibitors have been introduced as...
8.
Mouton W, Aguilhon L, Alcazer V, Carrer M, Franc P, Dupre C, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40058647
Background: Immune reconstitution (IR) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently monitored by measuring the absolute number of immune effectors. However, this approach does not capture functional immune...
9.
Frangoul H, Stults A, Bruce K, Domm J, Carroll C, Aide S, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40058646
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are inherited blood disorders caused by pathogenic variants of the β-globin gene. Historically, allogeneic hematopoietic stem cell transplantation (HSCT) from human leukocyte...
10.
Fu Z, Li B, Chai Y, Guo X, Chen X, Zhang L, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40057192
Background: Chronic active Epstein-Barr virus (CAEBV) infection is a severe, life-threatening condition characterized by persistent Epstein-Barr virus (EBV) infection and the clonal expansion of infected T or NK cells, leading...